ACE and coronary artery disorder: In a randomized controlled study including aspirin-treated patients with coronary artery disease (CAD; defined as < 50% stenosis in coronary angiography) comparing the impact RAAS blockade on platelet aggregation, irbesartan (an ARB) significantly reduced TXA2-induced platelet aggregation, whereas enalapril (an ACE inhibitor) had no effect on TXA2-induced platelet aggregation assessed by turbidometry [30].